Status:
COMPLETED
Clinical Study on the Treatment of Lower Respiratory Tract Infection With Pseudomonas Aeruginosa by Ceftazidime and Avibatam
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
MDRPA
Eligibility:
All Genders
18+ years
Brief Summary
Multidrug-resistant Gram-negative bacteria (MDR-GNB) is emerging globally as a pathogen of concern in healthcare-associated infections (HAIs), and a threat to public health.There has been an alarming ...
Eligibility Criteria
Inclusion
- patients with MDRPA infection diagnosed by clinicians
- patients treated with anti-Pseudomonas aeruginosa antibiotics for at least 72h
- patients older than 18 years old.
Exclusion
- Patients with human immunodeficiency virus infection, mental illness, a medication course of less than 72 hours, or incomplete data were excluded.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06992102
Start Date
January 1 2022
End Date
January 1 2025
Last Update
May 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 21000